Abstract
Introduction: The introduction of anti-HCV testing has been a milestone in medical history and markedly reduced transfusion-associated hepatitis C. Over the last 20 years, the performance of HCV antibody assays improved strikingly with sensitivities and specificities reaching >98% for most licensed tests. Still, a significant number of samples may yield borderline signal-to-cut-off ratios. Re-testing of samples and application of confirmatory recombinant blot assays or nucleic acid testing is time-consuming and costly. Moreover, false negative results should be avoided in particular in special risk groups such as immunocompromised patients. We here aimed to compare the performance of 4 licensed anti-HCV assays in samples with borderline signal-to-cut-off ratios obtained at a tertiary referral and transplant center.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
